» Articles » PMID: 32595582

High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study

Overview
Journal Front Neurol
Specialty Neurology
Date 2020 Jun 30
PMID 32595582
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy type 1 (DM1, MIM #160900), the most common muscular dystrophy among adults, is a multisystem disorder, which affects, besides the skeletal muscle, several other tissues and/or organs, including the gastrointestinal apparatus, with manifestations that frequently affect the quality of life of DM1 patients. So far, only few, mainly retrospective studies evaluated this specific topic in DM1, so we performed a perspective study, enrolling 61 DM1 patients who underwent an extensive diagnostic protocol, including administration of the Gastrointestinal Symptom Rating Scale (GSRS), a validated patient-reported questionnaire about GI symptoms, laboratory tests, liver US scan, and an intestinal permeability assay, in order to characterize frequency and assess correlations regarding specific gastrointestinal manifestations with demographic or other DM1-related features. Our results in our DM1 cohort confirm the high frequency of various gastrointestinal manifestations, with the most frequent being constipation (45.9%). γGT levels were pathologically increased in 65% of DM1 patients and GPT in 29.82%; liver ultrasound studies showed steatosis in 34.4% of patients. Significantly, 91.22% of DM1 patients showed signs of altered intestinal permeability at the specific assay. We documented a gender-related prevalence and severity of gastrointestinal manifestations in DM1 females compared to DM1 males, while males showed higher serum GPT and γGT levels than females. Correlation studies documented a direct correlation between severity of muscle weakness estimated by MIRS score and γGT and alkaline phosphatase levels, suggesting their potential use as biomarkers of muscle disease severity in DM1.

Citing Articles

Use of HSA female mice as a model for the study of myotonic dystrophy type I.

Carrascosa-Saez M, Colom-Rodrigo A, Gonzalez-Martinez I, Perez-Gomez R, Garcia-Rey A, Piqueras-Losilla D Lab Anim (NY). 2025; .

PMID: 40016516 DOI: 10.1038/s41684-025-01506-7.


The Gut Microbiota Involvement in the Panorama of Muscular Dystrophy Pathogenesis.

Russo C, Surdo S, Valle M, Malaguarnera L Int J Mol Sci. 2024; 25(20).

PMID: 39457092 PMC: 11508360. DOI: 10.3390/ijms252011310.


Altered drug metabolism and increased susceptibility to fatty liver disease in a mouse model of myotonic dystrophy.

Dewald Z, Adesanya O, Bae H, Gupta A, Derham J, Chembazhi U Nat Commun. 2024; 15(1):9062.

PMID: 39433769 PMC: 11494077. DOI: 10.1038/s41467-024-53378-z.


Disturbance of the human gut microbiota in patients with Myotonic Dystrophy type 1.

Mahdavi M, Prevost K, Balthazar P, Hus I, Duchesne E, Dumont N Comput Struct Biotechnol J. 2024; 23:2097-2108.

PMID: 38803516 PMC: 11128782. DOI: 10.1016/j.csbj.2024.05.009.


A Greek National Cross-Sectional Study on Myotonic Dystrophies.

Papadimas G, Papadopoulos C, Kekou K, Kartanou C, Kladi A, Nitsa E Int J Mol Sci. 2022; 23(24).

PMID: 36555146 PMC: 9778724. DOI: 10.3390/ijms232415507.


References
1.
Silvestri G, Maccora D, Perna A, Rossi S, Valenza V . Reader response: High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. Neurology. 2018; 90(17):814. DOI: 10.1212/WNL.0000000000005366. View

2.
Passeri E, Bugiardini E, Sansone V, Pizzocaro A, Fulceri C, Valaperta R . Gonadal failure is associated with visceral adiposity in myotonic dystrophies. Eur J Clin Invest. 2015; 45(7):702-10. DOI: 10.1111/eci.12459. View

3.
Achiron A, Barak Y, Magal N, Shohat M, Cohen M, Barar R . Abnormal liver test results in myotonic dystrophy. J Clin Gastroenterol. 1998; 26(4):292-5. DOI: 10.1097/00004836-199806000-00016. View

4.
Bianchi M, Leoncini E, Masciullo M, Modoni A, Gadalla S, Massa R . Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. J Neurol. 2016; 263(3):492-8. PMC: 7814867. DOI: 10.1007/s00415-015-8006-y. View

5.
Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P . Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001; 56(3):336-40. DOI: 10.1212/wnl.56.3.336. View